A Clinical Pharmacology Study of Multiple Doses of TA-7284 in Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I/II
Latest Information Update: 16 Jun 2014
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 07 Jun 2017 Biomarkers information updated
- 03 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2009 Planned end date changed from Dec 2008 to Feb 2009 as reported by ClinicalTrials.gov.